United BioSource Corporation
(UBC), a wholly owned subsidiary of Medco Health Solutions, Inc., today announced the acquisition of Total Healthcare Group (THG), a London-based international consultancy serving clients in the biopharmaceutical industry. THG provides global payer research, strategic planning, and global value dossiers for biopharmaceutical products.
THG, together with UBC’s existing value strategy and research services, will be led by THG’s Dr. Robert Hollamby, who has been appointed Senior Vice President at UBC.
“Demonstrating value and providing evidence-based research that allows stakeholders in the health care market to make important economic decisions surrounding biopharmaceuticals and devices is crucial in the market place,” said UBC President Mark Clein. “UBC helps clients respond effectively to the evolving health care environment by researching, communicating, and demonstrating value in medicines. The addition of THG significantly expands our capabilities and geographic reach and allows us to launch a comprehensive practice that we expect to be a leader in the global biopharmaceutical industry.”
Results International served as THG’s financial advisor in this transaction.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.